Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has announced that its subsidiary, hVIVO, will be presenting at the European Respiratory Society Congress being held on 7th – 9th September, 2020.
The presentation will discuss the safety and pathogenicity results of a new RSV infection model in older adults aged 60-75-year-old. This model enables the exploration of RSV vaccine-induced immune responses and efficacy in the context of potential immune senescence. It also enables the potential Identification of correlates of protection from RSV infection and disease in one of the vaccine’s target populations.
Oral presentation details:
Title: Late Breaking Abstract -Experimental Respiratory Syncytial Virus Infection in Adults 60-75 years
Authors: Alex J Mann, Maria Kalinova, Andrew Catchpole, Olesya Rusyn, Veronika Horvathova, Kingsley Eze, Marco De Sa, Alan S Bell
Date & Time: 9th September 2020 at 9:30am – 10.30am
Session Category: Airway infection: the microbiome and beyond
Presenter: Alex J Mann, Director of Clinical Sciences
Location: Online
Conference Reference Number: Channel 4
A copy of the presentation materials and the poster can be found here: https://hvivo.com/news-media/scientific-papers/
Alex J Mann, Director, Clinical Science, commented; “We are delighted to have been accepted to present at the prestigious ERS International Congress and share our findings. The data summarised in the presentation and ePoster highlights the model’s safety, disease characteristics, and suitability for the further assessment of vaccines and drugs targeted at the 60-75-year-old population, as well as its potential to continue that progression.”
